Raft of Japanese approvals for Novartis
This article was originally published in Scrip
Executive Summary
Novartishas received final approvals in Japan for four new products important to its business, following a series of positive recommendations in the latter months of last year. Xolair, Tasigna, Lucentis and Co-Dio are all now awaiting reimbursement price listing and should reach the market over the next few months.